Newburyport, Mass., November 3, 2026. UFP Technologies, Inc. (Nasdaq: UFPT), a trusted contract development and manufacturing organization specializing in comprehensive solutions for medical devices, sterile packaging and other highly engineered custom products, today reported net income of $20.6 million for its third quarter ended September 30, 2026, 25.8% higher than net income of $16.4 million for the third quarter of 2025. Net sales for the quarter ended September 30, 2026 were $172.4 million, 11.6% higher than 2025 third quarter sales of $154.6 million. Generally accepted accounting principles ("GAAP") and adjusted earnings per diluted common share outstanding ("EPS") for the quarter ended September 30, 2026 were $2.64 and $2.88, respectively. Net income for the nine-month period ended September 30, 2026 was $59.0 million, 16.2% higher than net income of $50.7 million for the same period in 2025. Net sales for the nine-month period ended September 30, 2026 were $500.6 million, compared to sales of $453.9 million in the same period of 2025. GAAP and adjusted EPS for the nine-month period ended September 30, 2026 were $7.56 and $8.28, respectively.
|
UFP Technologies, Inc. is a contract development and manufacturing organization specializing in single-use and single-patient medical devices. The company serves as an outsourcing partner to major medical device manufacturers, providing custom-engineered components and packaging for applications in minimally invasive surgery, infection prevention, wound care, wearables, orthopedic soft goods, and orthopedic implants. Its product portfolio includes protective drapes for robotic surgery, advanced wound care materials, disposables for surgical and endoscopic procedures, packaging for medical devices, components for cardiac implants, and dispenser coils for catheters. UFP Technologies operates in the medical, biopharma, and diagnostics sectors, utilizing manufacturing processes such as thermoforming, radio frequency welding, and micro-molding. The company was incorporated in 1993 and acquired CI Medical to expand its medical device printing capabilities. It maintains manufacturing facilities that are FDA registered and ISO 13485 certified, supporting customers who require compliance with regulatory standards for medical devices. Summarised from the company's own disclosures, fiscal year ended Feb 2026 |
Industry Medical Instruments & Supplies | Homepage ufpt.com |
| Sector Healthcare | IR page ufpt.com/investors | |
|
Tags
contract manufacturing, medical devices, single-use devices, wound care, orthopedics, minimally invasive surgery, infection control, biopharma, medical packaging, thermoforming, foam processing, CI Medical
|
Press page ufpt.com/news |
Metrics
| Valuation | |
|---|---|
| Market cap | $ 2.299B |
| Market cap (USD) | $ 2.299B |
| P/E | 30.35 |
| PEG | 1.70 |
| P/BV | 4.73 |
| P/S | 3.54 |
| P/OCF | 30.99 |
| P/FCF | 29.11 |
| Dividend yield | — |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | 17.8% |
| ROI | 12.2% |
| ROIC | 13.7% |
| Profit margin | 11.3% |
| Growth | |
|---|---|
| Revenue growing | Yes |
| Profits growing | Yes |
| Revenue up 3y | Yes |
| Revenue up 5y | Yes |
| Earnings growth 3y (net profit CAGR) | 17.8% |
| Quality | |
|---|---|
| Profitable | Yes |
| Margin expanding | No |
| Buying back stock | No |
| Diluting (TTM) | No |
| Debt/Equity | 19.8% |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | 22 |
| Quality score | 27.8% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
| Figure | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 | FY 2011 | FY 2010 | FY 2009 | FY 2008 | FY 2007 | FY 2006 | FY 2005 | FY 2004 | FY 2003 | FY 2002 | FY 2001 | FY 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 602.797M | 504.421M | 400.072M | 353.792M | 206.32M | 179.373M | 198.381M | 190.455M | 147.843M | 146.132M | 138.85M | 139.307M | 139.223M | 130.962M | 127.244M | 120.766M | 99.231M | 110.032M | 93.595M | 93.749M | 83.962M | 68.624M | 60.902M | 61.189M | 61.574M | 74.492M |
| Net profit | 68.313M | 58.981M | 44.924M | 41.789M | 15.886M | 13.369M | 19.75M | 14.311M | 9.21M | 7.97M | 7.593M | 7.559M | 11.276M | 10.895M | 10.784M | 9.408M | 5.982M | 5.116M | 4.159M | 2.515M | 659.091K | 871.261K | -1.516M | -233.795K | -3.043M | 1.081M |
| Free cash flow | 78.979M | 56.937M | 30.844M | 3.964M | 8.898M | 20.669M | 25.451M | 15.892M | 7.087M | 2.1M | -3.223M | -2.31M | 10.276M | 4.168M | 7.975M | 8.542M | 8.832M | 3.922M | 8.046M | 10.578M | -101.596K | -708.113K | -491.35K | 1.295M | -208.936K | 1.117M |
| Figure | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 | FY 2011 | FY 2010 | FY 2009 | FY 2008 | FY 2007 | FY 2006 | FY 2005 | FY 2004 | FY 2003 | FY 2002 | FY 2001 | FY 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Share price | 222.03 | 244.51 | 172.04 | 117.89 | 70.26 | 46.6 | 49.61 | 30.04 | 27.8 | 25.45 | 23.82 | 24.58 | 25.22 | 17.92 | 14.78 | 12.2 | 5.84 | 4.08 | 4.91 | 4.45 | — | — | — | — | — | — |
| Price performance 12m | -0.09 | 0.42 | 0.46 | 0.68 | 0.51 | -0.06 | 0.65 | 0.08 | 0.09 | 0.07 | -0.03 | -0.03 | 0.41 | 0.21 | 0.21 | 1.09 | 0.43 | -0.17 | 0.1 | — | — | — | — | — | — | — |
Filed figures
Lines the statements and their notes report beside the headline figures, read from the filings' XBRL as filed (no restatement applied), with figures computed from one filing's own lines. Cash-flow lines carry their cash direction: an outflow is negative. Each period links to its filing; a figure's period, report date and tag are in its tooltip.
| Figure | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Balance sheet detail | ||||||||||
| Trade receivables (USD) | 21.2M | 21.4M | 28.3M | 28.6M | 26.4M | 39.4M | 55.1M | 64.4M | 84.7M | 82.9M |
| ↳ YoY growth | +21.6% | +0.6% | +32.5% | +1.2% | -7.7% | +49.0% | +39.9% | +16.9% | +31.4% | -2.1% |
| ↳ 5y CAGR | +6.4% | +3.7% | +10.7% | +11.7% | +8.6% | +13.1% | +20.9% | +17.9% | +24.2% | +25.7% |
| Borrowings, current (USD) | 856,000 | — | 2.86M | — | 0.00 | 4M | 4M | 4M | 12.5M | 12.5M |
| Borrowings, non-current (USD) | — | — | 22.3M | — | 0.00 | 71M | 51M | 28M | 177M | 123M |
| Lease liabilities (USD) | — | — | 0.00 | 3.09M | 2.21M | 9.36M | 13.2M | 13.9M | 16.7M | 19M |
| Cash and deposits (USD) | 31.4M | 38M | 3.24M | 3.74M | 24.2M | 11.1M | 4.45M | 5.26M | 13.5M | 20.3M |
| Intangible assets (USD) | 318,000 | — | 22.2M | 21M | 19.7M | 67.6M | 68.4M | 64.1M | 144M | 141M |
| Right-of-use assets (USD) | — | — | 4M | 3.03M | 2.05M | 9.05M | — | 13.4M | 16.1M | 18.8M |
| Net debt (borrowings + leases - cash) (USD) | -30.5M | — | 21.9M | — | -22M | 73.2M | 63.7M | 40.6M | 193M | 134M |
| Cash flow detail | ||||||||||
| Operating cash flow (USD) | 9.39M | 17.5M | 21.3M | 31.2M | 25M | 14.3M | 17.7M | 41.3M | 66.6M | 91.9M |
| Purchases of property, plant and equipment (USD) | -7.29M | -10.4M | -5.43M | -5.78M | -4.37M | -5.4M | -13.8M | -10.5M | -9.66M | — |
| Change in receivables (cash effect) (USD) | -3.77M | -132,000 | -2.56M | -327,000 | 2.22M | -7.75M | -16.9M | -9.12M | 1.22M | 5.34M |
| Change in inventories (cash effect) (USD) | 51,000 | 1.29M | -2.3M | 1.3M | -366,000 | -4.5M | -19.6M | -16.6M | -4.69M | 3.9M |
| Change in payables (cash effect) (USD) | -596,000 | 93,000 | 1.11M | -2.47M | -681,000 | 102,000 | 9.13M | 1.55M | -1.14M | -1.09M |
| Interest paid (cash effect) (USD) | -66,000 | -47,000 | -1.3M | -664,000 | -71,000 | -53,000 | -2.72M | -3.54M | -7.89M | -9.86M |
| Income taxes paid (cash effect) (USD) | -3.56M | -3.88M | -3.46M | -1.26M | -2.48M | -5.91M | -13.2M | -10.6M | -12.8M | -3.56M |
| Share-based compensation (USD) | 1.06M | 1.07M | 1.21M | 1.59M | 1.81M | 2.43M | 3.21M | 4.64M | 6.84M | 8.85M |
| Operating cash flow before change in receivables (USD) | 13.2M | 17.6M | 23.9M | 31.6M | 22.8M | 22M | 34.6M | 50.5M | 65.4M | 86.6M |
| Free cash flow (OCF - PPE - intangibles) (USD) | 2.1M | 7.09M | 15.9M | 25.5M | 20.7M | 8.9M | 3.96M | 30.8M | 56.9M | — |
| Income detail | ||||||||||
| Research and development expense (USD) | 1.3M | 1.1M | 10.5M | 9.5M | 8.2M | 8.5M | 9.3M | 7.2M | 10.4M | 8.6M |
| ↳ 5y CAGR | +1.6% | -3.3% | +54.3% | +51.3% | +42.4% | +45.6% | +53.3% | -7.3% | +1.8% | +1.0% |
| Total comprehensive income (USD) | — | — | — | — | 13.4M | 15.9M | 41.2M | 45.8M | 54.5M | 76.2M |
| Comprehensive income to owners (USD) | — | — | — | — | 13.4M | 15.9M | 41.2M | 45.8M | 54.5M | 76.2M |
| Provision for credit losses (USD) | 126,000 | 116,000 | -50,000 | -52,000 | 13,000 | 179,000 | 293,000 | 15,000 | 213,000 | 31,000 |
| Credit cost ratio (credit losses / average receivables) (%) | 0.7% | 0.5% | 0.2% | 0.2% | 0.0% | 0.5% | 0.6% | 0.0% | 0.3% | 0.0% |
| Reported | Mar 16, 2018 | Mar 16, 2018 | Mar 13, 2020 | Mar 13, 2020 | Mar 16, 2023 | Mar 16, 2023 | Mar 16, 2023 | Aug 9, 2024 | Mar 3, 2025 | Feb 27, 2026 |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpMaterial events reported to the SEC on Form 8-K or 6-K, newest first. The link opens the filing itself on EDGAR. Press releases from the company's own website, newest first.
Scroll to first section Down Arrow
Newburyport, MA, October 29, 2026 – UFP Technologies, Inc. (Nasdaq: UFPT), a trusted contract development and manufacturing organization specializing in comprehensive solutions for medical devices, sterile packaging and other highly engineered custom products, today announced that the Company plans to report results for the third quarter on Tuesday, November 3rd, after the close of the stock market. The Company will hold a conference call to discuss the results on the following day, November 4th, at 8:30 AM Eastern time.
**Conference Call Information:
**Date: Wednesday, November 4, 2026
Time: 8:30 AM Eastern Time
Participants may join the call using the following dial-in numbers:
- USA/Canada: Toll-Free: 1-412-206-6478
- International: 1-833-890-4010
A live webcast of the conference call and accompanying materials will be available here .
A replay of the webcast will be accessible following the event on the Company’s Investor Relations website at https://ufpt.com/investors/ .
**About UFP Technologies, Inc.
**UFP Technologies is a trusted contract development and manufacturing organization specializing in comprehensive solutions for medical devices, sterile packaging and other highly engineered custom products. The Company’s single-use and single-patient devices and components are used across a wide range of medical products in segments including robotic assisted surgery, patient beds, infection control, cardiovascular, orthopedics and spine and wound car.
**Investor Contact:
**Jeff Elliott
Three Part Advisors, LLC
214-966-9014
**UFP Technologies Contact:
**Ron Lataille, CFO
978-234-0926
[email protected]
Newburyport, MA, September 9, 2026 — UFP Technologies, Inc. (Nasdaq: UFPT), a trusted contract development and manufacturing organization specializing in comprehensive solutions for medical devices, sterile packaging and other highly engineered custom products, today announced the acquisition of CI Medical
, further expanding the Company’s capabilities and complementing its existing breadth of material and technical expertise.
Founded in 1985 and headquartered in Norton, Massachusetts, CI Medical is a market leader in pad printing hard-to-stick materials for the medical device industry. The Company is ISO 9001:2015 certified and its team members are experts in precision printing on some of the industry’s most challenging substrates.
“CI Medical is a fantastic strategic fit for us,” said Mitch Rock, President and CEO of UFP Technologies. “They are a trusted development partner and a strong cultural fit, with a seasoned team that has deep expertise in medical manufacturing. Like us, they pride themselves on being true partners from concept to scale.”
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
ETFs Holding UFP Technologies, Inc.
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.
| ETF | Weight in ETF | Shares | Market value | As of |
|---|---|---|---|---|
| TMFS | 4.16% | 8,129 | $ 2.422M | Aug 31, 2026 |
| CSMD | 2.63% | 46,829 | $ 11.931M | Jul 31, 2026 |
| SMCO | 1.64% | 8,021 | $ 2.395M | Nov 17, 2026 |
| NBSM | 1.15% | 4,427 | $ 1.319M | Aug 31, 2026 |
| SSMG | 0.88% | 110 | $ 28.026K | Jul 31, 2026 |
| RUSC | 0.22% | 645 | $ 171.009K | Jun 30, 2026 |
| PSC | 0.18% | 15,566 | $ 4.127M | Jun 30, 2026 |
| IVSS | 0.17% | 170 | $ 45.072K | Jun 30, 2026 |
| AVSC | 0.15% | 15,697 | $ 4.686M | Nov 16, 2026 |
| RESM | 0.09% | 13 | $ 3,446.69 | Jun 30, 2026 |
| RILA | 0.06% | 92 | $ 23.44K | Jul 31, 2026 |
| DFAS | 0.05% | 57,295 | $ 17.527M | Nov 12, 2026 |
| DXUV | 0.02% | 3,726 | $ 1.14M | Nov 12, 2026 |
| MSSM | 0.01% | 279 | $ 83.128K | Aug 31, 2026 |
| DFAC | 0.01% | 32,160 | $ 9.838M | Nov 12, 2026 |
| DFUV | 0.01% | 4,811 | $ 1.472M | Nov 12, 2026 |
| DCOR | 0.01% | 10,513 | $ 3.216M | Nov 12, 2026 |
| DFUS | 0.00% | 2,899 | $ 886.833K | Nov 12, 2026 |
| DFAU | 0.00% | 1,665 | $ 509.34K | Nov 12, 2026 |
| EBI | 0.00% | 18 | $ 5,363.10 | Aug 31, 2026 |
| AVUS | 0.00% | 1,361 | $ 406.313K | Nov 16, 2026 |
| AVSU | 0.00% | 42 | $ 12.539K | Nov 16, 2026 |